168 followers
The authors of "mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Im…" (https://t.co/ItZw4zUjV1) included RRIDs in their paper! Thank you for making your #methodsmatter. #accelerateopenscience
4,153 followers
$lptx mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment (good primer as data nears) https://t.co/AN0ThcBhXv
4,153 followers
RT @marketfrankford: This study shows potential for $LPTX DKN-01 in breast cancer and melanoma. $LPTX https://t.co/u8U6jNt1H6
358 followers
RT @marketfrankford: This study shows potential for $LPTX DKN-01 in breast cancer and melanoma. $LPTX https://t.co/u8U6jNt1H6
114 followers
RT @marketfrankford: This study shows potential for $LPTX DKN-01 in breast cancer and melanoma. $LPTX https://t.co/u8U6jNt1H6
7,304 followers
RT @marketfrankford: This study shows potential for $LPTX DKN-01 in breast cancer and melanoma. $LPTX https://t.co/u8U6jNt1H6
393 followers
$LPTX Very good article! #Cancers #BreakingNews #biotech
485 followers
This study shows potential for $LPTX DKN-01 in breast cancer and melanoma. $LPTX https://t.co/u8U6jNt1H6
227 followers
Outstanding!
90,028 followers
RT @nolastevedore: @srqstockpicker $LPTX Published April 2021 in Molecular Cancer Research, although released online earlier "mDKN-01, a…
2,194 followers
@srqstockpicker $LPTX Published April 2021 in Molecular Cancer Research, although released online earlier "mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment" DKK1 has potential in many cancers: GEJ, breast, l
4,153 followers
4,153 followers
2,194 followers
@Pharmdca $LPTX Published April 2021 in Molecular Cancer Research in print, although released online earlier "mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment" Potential in many cancers: GEJ, breast, lung, p
1,975 followers
Anti-DKK1 #MonoclonalAntibody mDKN-01 reverses a DKK1 mediated innate immune suppression in the #TumorMicroenvironment and has additive efficacy with a PD-1 inhibitor. @LeapTherapeutic https://t.co/MzQJfgQZuf https://t.co/1PZPDzj7kQ
1,975 followers
Anti-DKK1 #MonoclonalAntibody mDKN-01 reverses a DKK1 mediated innate immune suppression in the #TumorMicroenvironment and has additive efficacy with a PD-1 inhibitor. @LeapTherapeutic https://t.co/zNBP0WMwUr https://t.co/SEXxN0qlH1
794 followers
Check out this new @MCR_AACR publication in which we produced the mDKN-01 antibody which was found to enhance innate immune response in the tumor microenvironment. https://t.co/F3UlSkRVmr
1,384 followers
mDKN-01, a Novel Anti-DKK1 Monoclonal Antibody, Enhances Innate Immune Responses in the Tumor Microenvironment. by Haas MS, Kagey MH, Heath H, Schuerpf F, Newman W, Rottman JB https://t.co/6NIoNs9ef4
1,975 followers
Anti-DKK1 #MonoclonalAntibody mDKN-01 reverses a DKK1 mediated innate immune suppression in the #TumorMicroenvironment and has additive efficacy with a PD-1 inhibitor. @LeapTherapeutic https://t.co/icA0auACbJ https://t.co/uEzu01fP6u
121 followers
RT @LeapTherapeutic: “The additive effect of DKK1 and PD-1 co-blockade further supports Leap’s Phase 2 DisTinGuish study, investigating DKN…
10 followers
RT @Kevin_W81: $LPTX
10 followers
RT @LeapTherapeutic: “The additive effect of DKK1 and PD-1 co-blockade further supports Leap’s Phase 2 DisTinGuish study, investigating DKN…
74 followers
RT @Kevin_W81: $LPTX
333 followers
$LPTX
12,627 followers
$LPTX
74 followers
RT @LeapTherapeutic: “The additive effect of DKK1 and PD-1 co-blockade further supports Leap’s Phase 2 DisTinGuish study, investigating DKN…
629 followers
“The additive effect of DKK1 and PD-1 co-blockade further supports Leap’s Phase 2 DisTinGuish study, investigating DKN-01 and Tislelizumab with and without chemotherapy” - Jay Baum, Vice President and Head of Translational Medicine at Leap Therapeutics. ht